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Abstract
Background: The aim of this study was to describe the extent of the HIV epidemic among women in the
Republic of Georgia and to identify factors associated with HCV co-infection in this population.
Findings: All women aged ≥18 years who were diagnosed with HIV between 1989 and 2006 were identified
through the National HIV/AIDS surveillance database. Medical records were reviewed for demographic
characteristics, risk factors and HCV serostatus. A total of 249 women were identified. Only 4% declared injection
drug use (IDU); sex work was reported by 9%. Substantial risk factors were identified among the women’s sexual
partners, nearly 69% of whom were IDUs, 84% were HIV positive and 66% HCV positive. Seventeen percent of
women were seropositive for HCV. Factors significantly associated with HCV seropositivity in bivariate analyses
among non-IDU women were partner IDU+ [Prevalence ratio (PR): 4.5 (95% CI: 1.4, 14.2)], and partner HCV+ [PR: 7.2
(95% CI: 1.8, 29.5)].
Conclusions: The HIV epidemic in the Republic of Georgia is closely tied to the IDU community. Evidence-based
interventions targeting IDU and partners of IDU are urgently required to halt the spread of the HIV epidemic in the
country.
Findings
The Newly Independent States (NIS) of Eurasia have the
highest rates of HIV infection in the region [1,2]. The
HIV epidemic here has been closely linked with the
socioeconomic and political upheavals of the early 1990s
and the collapse of the Soviet Union. The emergence of
drug markets and injection drug use (IDU) is now the
major driver of the epidemic in the region [3,4]. The bur-
geoning IDU population was accompanied by an explo-
sive spread of hepatitis C virus (HCV) and HIV; today,
the IDU population is almost universally infected with
HCV and the majority is co-infected with HIV [5-7].
Formerly part of the Soviet Union, Georgia is an inde-
pendent nation with a population of about 4.5 million.
Compared to other NIS, Georgia’s HIV epidemic started
later and grew more slowly. The first case of HIV was
reported in 1989; as of December 31, 2006, a cumulative
1,156 HIV cases had been reported. Nearly 78% of cases
are men and 22% women. Although the estimated HIV
prevalence in Georgia is low (< 0.1%), the rate of new
infections has risen each year (see Figure 1). Among
men, approximately 80% of cases are attributable to
IDU. The vast majority of HIV positive women (93%)
were exposed through heterosexual contact.
Similar to other countries in the region, the spread of
HCV infection in Georgia was partially associated with
the rise in IDU. Multiple studies have found strong
associations between male gender, IDU and HCV infec-
tion. While HIV prevalence in IDUs is relatively low
(2.2%), HCV infection is common (70%) [8-11]. In these
studies IDUs almost exclusively were male. Little is
known about the HCV transmission risks among HIV-
positive women. This study describes the HIV epidemic
among women and identifies risk factors associated with
HCV seropositivity among HIV positive women.
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Methods
The study was conducted at the Infectious Diseases,
AIDS & Clinical Immunology Research Center (IDA-
CIRC), which is Georgia’s referral institution for HIV
diagnosis, treatment and care. IDACIRC is the country’s
sole institution providing confirmation testing of initially
positive HIV cases. All individuals with a confirmed
HIV diagnosis are first seen at IDACIRC in Tbilisi. In
addition to clinical assessment the initial exam includes
information on socio-demographic characteristics and
risk factors. Data are subsequently entered into HIV/
AIDS electronic database operated by the IDACIRC.
The database contains information on all individuals
with confirmed HIV infection since the first case
reported in 1989.
The IDACIRC also coordinates treatment for indivi-
duals infected by HIV. Treatment for HIV/AIDS in Tbi-
lisi, the nation’s capital, has been provided at the
IDACIRC since the beginning of the epidemic. In 2006,
two regional AIDS treatment facilities were opened, pro-
viding local treatment options for individuals living out-
side Tbilisi after initial assessment.
Study Population
We included all women at least 18 years of age diag-
nosed with HIV between 1989 and 2006 who were iden-
tified and received evaluation and treatment at the
Tbilisi IDACIRC office.
Data
The database contains person’s name, demographic
characteristics, medical identification, date of HIV diag-
nosis, disease stage, and exposure risk category, among
other factors. Medical records at the IDACIRC were
reviewed for demographic characteristics, risk factors
and HCV serostatus.
Factors
Demographic characteristics abstracted included age,
ethnicity, educational level, employment, marital status,
residence and refugee (internally displaced) status.
Risk factors for HIV are ascertained during patients’
initial examinations with detailed questions regarding
IDU, sexual activity, history of sexually transmitted
infection (STI), viral hepatitis, commercial sex work, risk
factors of the patient’s last regular sexual partner(s), and
medical care-related risk factors (e.g., history of invasive
medical manipulations and blood transfusion). Informa-
tion on patient’s main sexual partner was extracted
from the women’s detailed intake exam records; addi-
tionally partners’ medical records were reviewed for
those women with HIV positive partners registered at
the IDACIRC.
Screening for HCV infection is routinely performed
among persons with HIV. Co-infection is defined as the
presence of HCV antibodies detected by second- and
third-generation enzyme immunoassay and documented
in the medical record [12].
Statistical Analysis
All statistical analyses were performed using SAS v.
9.1.3. Descriptive statistics were used to examine vari-
able distributions. Bivariate associations between risk
factors and HCV co-infection were assessed using preva-
lence ratios (PR) and their 95% confidence intervals (CI).
Multivariate analyses by stratified analysis and Poisson
regression with robust variance estimates were utilized
to assess associations between multiple covariates and
HCV co-infection [13,14].
Ethical Approval
Study was approved by the Institutional Review Boards
(IRB) of the IDACIRC and University at Albany.
Results
A total of 249 women aged 18 years or older with a
confirmed HIV diagnosis were identified from the HIV/
AIDS surveillance database. HCV status was available
for 244 women. Because of substantial missing data,
analyses were generally limited to 228 women. Women
with complete and incomplete data did not differ in
terms of demographic characteristics or personal beha-
viors. The majority of missing data resulting in exclu-
sion from analyses was partner-related risk factors.
To understand the extent of the HIV epidemic, we
reviewed surveillance data for women by source of iden-
tification. Most of the women in our study were identi-
fied through HIV case investigation, self referral,
prenatal screening or referral from an HIV lab. Of




















Figure 1 HIV incidence among adult men and women in the
Republic of Georgia, 2000-2006.
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screening program began in 2003, 32 (0.0004) were
HIV-positive, and of these, 21 (66%) reported partner-
related risk factors: IDU, HIV+ and HCV + status. The
other 11 were not known to have any IDU connection.
Other important sources of identification included case
investigation, referral from medical facilities and self-
referral. The majority of these women had documented
connection to IDUs (i.e., partner was IDU) ranging from
52% to 80%.
Among the 228 HIV+ women whose medical records
were abstracted, 68% were younger than 35 years of age
(mean age: 31 years). The vast majority were ethnic
Georgians (89%), unemployed (76%) and married (68%)
at the time of diagnosis. Only 32% were college gradu-
ates. Thirteen percent were internally displaced from
occupied regions of Georgia.
Relatively few women reported major behavioral risk
factors for HIV or HCV infection. Only ten (4%) women
declared use of injection drugs; commercial sex work was
reported by 21 (9%) women. While 36% of women had
more than one lifetime sexual partner, overall more than
half reported no personal risk behavior for HIV other
than having a partner who is IDU. The sexual partners
brought substantial risk factors to the relationship: the
majority were HIV positive (84%), nearly 69% gave a his-
tory of IDU, and approximately 66% had documented
HCV antibodies. About 30% of women had a history of
an STI. Approximately half of the women reported a his-
tory of at least one invasive medical procedure.
Among the 10 IDU women, eight (80%) were positive
for HCV antibodies, while among the 218 who did not
report IDU, 32 (14.7%) women were HCV seropositive.
Because of the strong association between IDU and
HCV infection [PR: 5.4 (95% CI: 3.5-8.5)], IDU women
were excluded from further analyses.
Factors significantly associated with HCV seropositivity
in bivariate analyses among self-declared non-IDU women
were IDU partner [PR: 4.5 (95% CI: 1.4-14.2)], and partner
HCV seropositivity [PR: 7.2 (95% CI: 1.8-29.5)]. In a multi-
variate Poisson regression (with robust variance estimates),
only partner HCV positivity remained significantly asso-
ciated with the woman’s HCV co-infection: PR 8.1 (95%
CI: 1.9, 34.0) (Table 1). Assessment of the strongest bivari-
ate risk factors for HCV-coinfection in a multivariate man-
ner provided insight into the regression model’s results
(Table 2). A strong association existed between the part-
ner’s IDU-status and the woman’s HCV seropositivity;
however, due to substantial colinearity, it was the partner’s
HCV status that was the most predictive factor for women
being infected with HCV.
Discussion
This study examined all known HIV positive women in
Georgia and found that the HIV epidemic remains
closely tied to the IDU community. The majority of
HIV positive women (70%) have a documented connec-
tion to the IDU community through either their own
IDU (n = 10) or a partner with IDU (n = 163) or HCV
(a proxy for IDU among men in the region, n = 152).
While few women reported IDU, HCV in women is
common for those with partners who are HCV seroposi-
tive. The fact that most women reported no risk beha-
vior related to HCV does not necessarily mean that the
infection was transmitted through heterosexual expo-
sure. Although sexual transmission of HCV may occur
[15,16], the overwhelming evidence suggests that the
efficiency of transmission by the sexual route is very
low. Longitudinal studies among monogamous hetero-
sexual couples indicate no or low risk associated with
acquisition of HCV through sexual intercourse. Vandelli
and colleagues reported an incidence rate of 0.37/1,000
person-years (py) among monogamous heterosexual
couples with over 10 years of follow-up [17]. In another
follow-up study, incidence of HCV acquisition was esti-
mated at 2.33/1,000py [18]. Two other studies reported
an absence of seroconversion among spouses [19,20].
On the other hand, previous studies have shown that
those with risky sexual behavior, STIs (particularly geni-
tal ulcerative diseases), and co-infection with HIV have
an increased risk of HCV acquisition [21-26]. Consistent
with these reports our study suggests that having sexual
contact with HCV positive partners is an important co-
factor for being HCV positive among HIV infected
women in Georgia. However, it is unlikely that the high
prevalence of HCV in our study was solely due to the
sexual exposure to the virus.
Evidence suggests that IDU is one of the most effi-
cient modes of HCV transmission,[27] which can occur
shortly after initiation of IDU [28]. Within the ALIVE
Study, 65% of participants with brief IDU were positive
for HCV antibodies [29]. And HCV seroprevalence
exceeding 70% was reported in a similar study in South-
ern China [30]. Cohort studies among persons with IDU
showed that the incidence of HCV was greatest within
the first year of follow-up and ranged from 16.1/100py
to 41.8/100py [31-33]. The same studies reported signifi-
cantly lower rates for HIV seroconversion over the same
time of observation: 0.8/100py to 7.2/100py, likely due
to the difference in baseline prevalence [31-33]. The
greater transmissibility of HCV through percutaneous
blood exposures compared to HIV suggests that even a
single instance of sharing injection equipment or acci-
dental intrafamilial transmission by sharing razors or
needles for medicine could be sufficient [34]. This cir-
cumstance might have been overlooked in our study as
such data has not been collected.
Relatively limited education and intervention has been
targeted at the IDU community in Georgia. Primary
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prevention of IDU in the country has been implemented
on a small scale by Non-Governmental Organizations
(NGO) as fragmentary programs. Although harm reduc-
tion interventions (syringe exchange and substitution
therapy) are carried out on a more systematic scale, the
current coverage does not meet existing demand [35].
More regular, coordinated prevention interventions at
the school, community and family level are needed. An
important component may be educating women about
household exposures to HIV and HCV.
As with all studies, caveats require mention. First, the
study was based on chart review and data collected by
Table 1 Association between risk factors and hepatitis C virus (HCV) co-infection among 218 self-declared
non-injection drug using women with HIV in the Republic of Georgia
HCV Positive Bivariate analysis Multivariate analysis*
Total N N % PR (95% CI) PR (95% CI)
Demographic Characteristics
Age
18-34 150 25 16.7 1.6 (0.7, 3.6)
≥35 68 7 10.3
Education
No degree 147 21 14.3 0.9 (0.5, 1.8)
College/university degree 71 11 15.5
Employment
Unemployed 163 27 16.6 1.8 (0.7, 4.5)
Employed 55 5 9.1
Marital status
Not married 57 8 14.0 0.9 (0.4, 1.9) 1.3 (0.6, 2.7)
Married 161 24 14.9
Internally displaced
Yes 29 4 13.8 0.9 (0.4, 2.5)
No 189 28 14.8
Medical Care
History of surgery
Yes 98 14 14.3 0.9 (0.5, 1.8) 0.8 (0.4, 1.7)
No 120 18 15.0
History of STI
Yes 59 8 13.6 0.9 (0.4, 1.9) 1.3 (0.6, 2.7)
No 159 24 15.1
Personal Risk Behaviors
Sex work
Yes 14 1 7.1 0.5 (0.1, 3.2)
No 204 31 15.2
Number of sexual partners
> 1 partner 70 10 14.3 0.9 (0.5, 1.9)
1 partner 148 22 14.9
Partner Related Factors
Partner risk factor
IDU documented 149 29 19.5 4.5 (1.4, 14.2)
IDU not documented 69 3 4.4
Partner HIV status
HIV positive 185 31 16.8 5.5 (0.8, 39.1)
HIV negative/no regular partner 33 1 3.0
Partner HCV status
HCV positive 147 30 20.4 7.2 (1.8, 29.5) 8.1 (1.9, 34.0)
HCV negative/no regular partner 71 2 2.8
* Partner IDU status and partner HIV status were dropped from the model due to colinearity with partner’s HCV status. Initial multivariate model included all
variables. The final model retained variables “Marital status”, “history of STI” and “Marital status” because of confounding effect.
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physicians as part of clinical intake interviews. While all
physicians at the IDACIRC are trained to work with risk
groups, some patients may not feel comfortable in reveal-
ing IDU [36,37]. Second, injection-related exposure is
associated with deeply ingrained cultural attitudes about
IDU that highly stigmatize women, potentially increasing
the likelihood of non-disclosure of IDU, especially if use
is occasional. Third, measurement of exposures to HCV
through medical and dental care was nonspecific. How-
ever, the relatively small risk related to medical care can-
not explain the HCV distribution seen. Fourth, while
majority of women with multiple sexual partners were
divorced, partner information was available only on the
last regular partner. Finally, 21 women were missing data
either on their own HCV status or partner-related infor-
mation, and were excluded from analysis.
An explosive increase in the size of the IDU popula-
tion in NIS has placed drug abusers at the core of the
HIV epidemic in the region, as well as a parallel HCV
epidemic [4,38]. It is estimated that more than 1% of
the population in Eastern Europe abuses injection opi-
ates [39]. Our study suggests that the HIV epidemic in
Georgia remains largely concentrated around the IDU
community. Of the almost 80,000 pregnant women
screened for HIV in Georgia, 32 women were HIV
infected,[40,41] 66% of whom had a documented con-
nection with the IDU community. Given the potential
for undocumented IDU, some of the remaining 11
women also may be connected to this high-risk commu-
nity or represent further transmission of HIV into the
general community. There is a clear need for evidence-
based interventions targeting persons with IDU and
their partners, especially educational activities for young
women. Mercifully, Georgia still has the chance to halt
the spread of the HIV epidemic.
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